發(fā)布時間：2019-07-26 05:30

【摘要】：正神經母細胞瘤(neuroblastoma,NB)是常見的兒童惡性腫瘤,在手術、放化療及介入等多種手段綜合治療下,總體療效仍然極差。近年來研究發(fā)現(xiàn),果蠅zeste基因增強子同源物2(enhancer of zeste homolog 2,EZH2)能抑制相關抑癌基因,明顯增加神經母細胞瘤發(fā)生、發(fā)展的風險~([1])。GSK126是一種新型的選擇性EZH2抑制劑~([2-3]),其在實體瘤方面的藥效探究目前相對較少。本文將對GSK126在神經母細胞瘤
[Abstract]:Positive neuroblastoma (neuroblastoma,NB) is a common malignant tumor in children. Under the combined treatment of surgery, radiotherapy, chemotherapy and intervention, the overall curative effect is still very poor. In recent years, it has been found that zeste gene enhancer 2 (enhancer of zeste homolog 2, EZH2) can inhibit related tumor suppressor genes and significantly increase the risk of neuroblastomas ([1]). GSK126 is a new selective EZH2 inhibitor ([2 鈮，

本文編號：2519362